Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance
February 26 2024 - 6:58PM
Business Wire
Quanterix Corporation (NASDAQ: QTRX) today announced that it has
rescheduled the release of its financial results for the fourth
quarter and year ended December 31, 2023 and the associated
conference call in order to more closely align the release of such
results with the filing of its Annual Report on Form 10-K for the
year ended December 31, 2023, the deadline for which is February
29, 2024. The investor call will now be held on Thursday, February
29, 2024.
Quanterix expects 2023 revenue, gross margin and cash usage to
be in line with guidance provided on January 10, 2024.
Quanterix expects to issue a press release regarding its fourth
quarter 2023 and full year 2023 financial results prior to the
conference call. The press release will be posted on the Quanterix
website at http://www.quanterix.com. In conjunction with this
announcement, the Company will host a conference call on February
29, 2024 at 4:30 p.m. E.T. Click here to pre-register for the
conference call and obtain your dial-in number and passcode.
Previously obtained dial-in numbers and passcodes may be used for
the rescheduled call.
Interested investors can also listen to the live webcast from
the Event Details page in the Investors section of the Quanterix
website at http://www.quanterix.com. An archived webcast replay
will be available on the Company’s website for one year.
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive
biomarker detection is driving breakthroughs only made possible
through its unparalleled sensitivity and flexibility. The Company’s
Simoa technology has delivered the gold standard for earlier
biomarker detection in blood, serum or plasma, with the ability to
quantify proteins that are far lower than the Level of
Quantification of conventional analog methods. Its industry-leading
precision instruments, digital immunoassay technology and
CLIA-certified Accelerator laboratory have supported research that
advances disease understanding and management in neurology,
oncology, immunology, cardiology and infectious disease. Quanterix
has been a trusted partner of the scientific community for nearly
two decades, powering research published in more than 2,700
peer-reviewed journals. Find additional information about the
Billerica, Massachusetts-based company at https://www.quanterix.com
or follow us on Twitter and LinkedIn.
Forward-Looking Statements
Final financial information is subject to completion of the
Company’s normal quarter and year-end close procedures and the
audit of the Company’s financial statements for the year ended
December 31, 2023, which are ongoing. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as "may,"
"will," "expect," "plan," "anticipate," "estimate," "intend" and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements include, but are not limited to,
statements about Quanterix’s financial performance and are subject
to a number of risks, uncertainties and assumptions.
Forward-looking statements in this press release are based on
Quanterix’s expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties. Factors that may cause Quanterix’s actual
results to differ from those expressed or implied in the
forward-looking statements in this press release include, but are
not limited to, those described in our periodic reports filed with
the U.S. Securities and Exchange Commission, including the "Risk
Factors" sections contained therein. Except as required by law,
Quanterix assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240226752540/en/
Media: PAN Communications Maya Nimnicht 510-334-6273
quanterix@pancomm.com Investor Relations:
ir@quanterix.com
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From May 2024 to Jun 2024
Quanterix (NASDAQ:QTRX)
Historical Stock Chart
From Jun 2023 to Jun 2024